Over the last ten years, the increasing size and complexity of research in the human microbiome has resulted in an ongoing evaluation of many concepts of health and disease, including diseases impacting the CNS.
Emerging data suggests that there is a link between changes in the gut
microbiome and neurological diseases and disorders. This workshop will
outline recent scientific advances in unraveling the gut-brain connections and potential pathways to harness these findings for novel therapeutic approaches.
Join Prof. Sarkis Mazmanian in an introductory workshop showing the most important topics to consider when conducting research in the gut brain axis including:
• Learning what we already know about the connection between gut
microbiota and the brain – Probe data and experience from the broader
• Use recent finding to develop a new class of therapeutics for neurological
Sarkis Mazmanian, Caltech and Co-Founder, Axial Biotherapuetics
Sarkis K Mazmanian, PhD, is the Louis & Nelly Soux Professor of Microbiology in the Division of Biology & Biological Engineering at the California Institute of Technology. His laboratory focuses on the study of beneficial bacterial molecules from the human gut microbiome as novel therapies for immunologic and neurologic disorders, with a specific focus on developing probiotic treatments for autism. He is a founder of 2 biotech companies, and has or currently serves on the Scientific Advisory Board of over a dozen companies, academic centers and not-for-profit foundations.
Emeran Mayer, Oppenheimer Center for Neurobiology of Stress, Division of Digestive Diseases, UCLA
Dr Emeran Mayer is a Professor in the Departments of Medicine, Physiology and Psychiatry at the David Geffen School of Medicine at UCLA, Executive Director of the Oppenheimer Center for Neurobiology of Stress, and Co-director of the CURE: Digestive Diseases Research Center at UCLA. He has 30 years experience in the study of clinical and neurobiological aspects of how the digestive system and the nervous system interact in health and disease. He has published over 320 peer reviewed articles, co-edited four books, and organized several interdisciplinary symposia in the area of visceral pain and mind body interactions. His current research focuses on the role of the gut microbiota in brain gut interactions in health, chronic visceral pain and obesity.
The development of the infant gut microbiome can be influenced by multiple complex factors, including mode of delivery, antibiotic exposure, and infant feeding patterns. Although a stable microbiome may not be established until 1 to 3 years after birth, the infant gut microbiota appears to be a very important predictor of health outcomes in later life.
With insight from Susanne Wolf at the Max Delbruck Center for Molecular Medicine, learn how new research within the infant microbiome and its interaction with host genetics have shown to be related to long term infant health and behavioral development.
As part of this interactive workshop session, five core components of infant microbiome research will be covered:
• Mode of Delivery – How does the mode of delivery impact variation in the infant microbiome?
• Pre and Postnatal Antibiotic Exposure – Looking at effects of antibiotic exposure, microbial colonization diversity, as well as their contribution to early-onset of disease
• Infant- Feeding Patterns – How new-born diet represents an essential factor related to the establishment of the gut microbiota
• Preterm Birth – The relationship between preterm birth and subsequent risk for gut microbial dysbiosis and associations with inflammatory factors
• In Utero Conditions – How environmental perturbations including maternal stress during pregnancy have been associated with neurodevelopmental disorders and gastrointestinal dysfunction
Susanne Wolf, Principal Investigator, Max Delbruck Center for Molecular Medicine
Dr. Wolf studied ethology at the Humboldt University of Berlin and then undertook a PhD in Neuroimmunology. Combining both subjects, she then turned her attention to the field of psychoneuroimmunology, first at the US National Institutes of Health (NIH) and later at Stanford University, USA. After returning to the Max Delbrück Center for Molecular Medicine in Berlin she began her investigations into the cross-talk between different cells within the brain and from the periphery in the context of psychiatric disorders.